Core Insights - Immuneering Corporation (IMRX) has entered into a clinical supply agreement with Eli Lilly (LLY) for the KRAS G12C inhibitor, olomorasib (LY3537982) [1] - The agreement supports a planned phase II study evaluating Immuneering's atebimetinib (IMM-1-104) in combination with olomorasib for treating advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) [2] - Immuneering's shares rose by 21.7% following the announcement, and the stock has increased by 170.5% year-to-date compared to the industry's 4.1% rise [2][3] Agreement Details - The combination of atebimetinib and olomorasib is expected to provide a vertical blockade of the RAS-MAPK pathway, with preclinical data showing enhanced tumor regression and prolonged survival compared to monotherapy [5] - This is Immuneering's second collaboration announcement in 2025, following a similar agreement with Regeneron Pharmaceuticals to evaluate atebimetinib with Libtayo for advanced NSCLC [6][7] - In both agreements, Immuneering retains full worldwide development and commercialization rights to atebimetinib [8] Ongoing Studies - Immuneering is advancing atebimetinib in other cancer studies, including a phase IIa study in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer [9] - Preliminary data from this study indicated a 94% overall survival and 72% progression-free survival at six months, with updated data expected later in Q3 2025 [10] - The company plans to initiate a pivotal study for atebimetinib in combination with modified gemcitabine/nab-paclitaxel in 2026, pending regulatory feedback [11]

Core Viewpoint - Immuneering Corporation has announced a clinical supply agreement with Eli Lilly for the evaluation of atebimetinib in combination with olomorasib in a Phase 2 trial targeting advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations [1][2] Group 1: Clinical Development - The agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib, a novel dual MEK inhibitor, in combination with olomorasib [1] - Immuneering is also evaluating atebimetinib in combination with Regeneron's anti-PD-1 therapy Libtayo in advanced NSCLC patients [1] - The combination aims to provide a vertical blockade of the RAS-MAPK pathway, potentially improving treatment outcomes in patients with limited options [3] Group 2: Product and Pipeline - Immuneering maintains global development and commercialization rights to atebimetinib [4] - The company is developing Deep Cyclic Inhibitors, with atebimetinib designed to improve durability and tolerability for MAPK pathway-driven tumors [5] - Atebimetinib is currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]